ArticleCureus2020
Region-Wise Distribution of Schizophrenia With Cannabis Abuse and Medication Non-Compliance in the United States: A Nationwide Analysis of 51,975 Hospitalizations.
Article in Cureus, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 5 citations in OpenAlex.
- Management of schizophrenia and comorbid substance use disorders: expert review and guidance.Annals of general psychiatry · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives To understand the region-wise differences in demographics, comorbid substance abuse, and hospital outcomes in adult schizophrenia inpatients with cannabis abuse and medication non-compliance. Methods We included 51,975 adults (18-65 years) from the Nationwide Inpatient Sample (2012 to 2014) with a primary diagnosis of schizophrenia and comorbid diagnosis of cannabis abuse and medication non-compliance. We used descriptive statistics and linear-by-linear association to evaluate the region-wise differences in demographics and comorbid substance abuse. Analysis of variance was used for continuous variables such as length of stay (LOS) and total charges during hospitalization to measure the differences across the regions. Results Our study inpatients were from the United States regions: northeast ([NE] 30.4%), midwest ([MW] 24.3%), south (27.3%), and west (18%). A higher proportion of young adults (age: 18-35 years; overall total: 62.4%) were from the south (65.1%) and the NE (64.3%) regions. The study population comprised majorly of males in all the regions, ranging from 78.6% to 82.2% (overall total: 80.5%). The west region comprised majorly of whites (42.6%), whereas all other regions majorly had blacks, with the highest seen in the MW (63.2%) and south (63%) regions. The most prevalent comorbid substances in the study inpatients were tobacco (46.3%) and alcohol (32.3%). The mean LOS and total charges for the hospitalization were much higher in the NE region (LOS: 15.8 days; total charges: $44,336). Conclusion Cannabis abuse and medication non-compliance in schizophrenia patients were prevalent in the NE region of the United States and in the overall regions, and affects young adults, males, and Blacks from low-income families. This is associated with higher hospitalization stay and cost, which indirectly increase the healthcare burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.